IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia

Bulian et al.
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia

Pietro Bulian1*, Davide Rossi2, Francesco Forconi3, Giovanni Del Poeta4, Francesco Bertoni5, Emanuele Zucca5, Marco Montillo6, Gabriele Pozzato7, Giovanni D’Arena8, Dimitar G Efremov9, Roberto Marasca10, Francesco Lauria3, Gianluca Gaidano2, Valter Gattei1† and Luca Laurenti11†

Abstract

Background: Prognostic index for survival estimation by clinical-demographic variables were previously proposed in chronic lymphocytic leukemia (CLL) patients. Our objective was to test in a large retrospective cohort of CLL patients the prognostic power of biological and clinical-demographic variable in a comprehensive multivariate model. A new prognostic index was proposed.

Methods: Overall survival and time to treatment in 620 untreated CLL patients were analyzed retrospectively to evaluate the multivariate independence and predictive power of mutational status of immunoglobulin heavy chain variable gene segments (IGHV), high-risk chromosomal aberration such as 17p or 11q deletions, CD38 and ZAP-70 expression, age, gender, Binet stage, β2-microglobulin levels, absolute lymphocyte count and number of lymph node regions.

Results: IGHV mutational status and 17p deletion were the sole biological variables with independent prognostic relevance in a multivariate model for overall survival, which included easily measurable clinical parameters (Binet staging, β2-microglobulin levels) and demographics (age and gender). Analysis of time to treatment in Binet A patients below 70 years of age showed that IGHV was the most important predictor. A novel 6-variable clinical-biological prognostic index was developed and internally validated, which assigned 3 points for Binet C stage, 2 points/each for Binet B stage and for age > 65 years, 1 point/each for male gender, high β2-microglobulin levels, presence of an unmutated IGHV gene status or 17p deletion. Patients were classified at low-risk (score = 0-1; 21%), intermediate-risk (score 2-5; 63% of cases), high-risk (score 6-9; 16% of cases). Projected 5-year overall survival was 98%, 90% and 58% in low-, intermediate- and high-risk groups, respectively. A nomogram for individual patient survival estimation was also proposed.

Conclusions: Data indicate that IGHV mutational status and 17p deletion may be integrated with clinical-demographic variables in new prognostic tools to estimate overall survival.

Keywords: Chronic lymphocytic leukaemia, Prognosis, Prognostic score, Nomogram

* Correspondence: pbulian@cro.it
† Contributed equally
1Clinical and Experimental Onco-Hematology Unit, IRCCS Centro di Riferimento Oncologico, via Franco Gallini 2, 33170 Aviano (PN), Italy
Full list of author information is available at the end of the article
Background
According to the updated National Cancer Institute-Working Group (NCI-WG) guidelines, indication for treatment of chronic lymphocytic leukemia (CLL) still depends on clinical stage and disease activity [1]. In this context, measurements of biological prognostic markers, namely CD38, ZAP-70, mutational status of immunoglobulin heavy chain variable gene segments (IGHV), are judged as mandatory in the context of clinical trials, but not in general practice, since they fail to influence therapeutic decisions [1]. The only exception is represented by analyses of chromosomal aberrations by interphase fluorescence in-situ hybridization (FISH), given the presence of high-risk cytogenetic lesions (del11q and del17p), which may predict resistance to chemotherapy-based treatments [2]. Wierda et al. [3] proposed to combine a set of clinical risk factors, i.e age, gender, Rai staging, absolute lymphocyte count (ALC) and number of involved lymph node regions (LNR), with an inexpensive and widely available serum marker such as beta2-microglobulin (β2-M) to develop a prognostic index (PI) stratifying patients in three risk groups with different expected median survival, and a nomogram, estimating individual patient survivals. This model was subsequently validated in independent patients series also using time to first treatment as end-point [4-8]. A reduction of this model from six to four variables, i.e. age, gender, β2 M levels and Binet staging, was also shown to predict survival with equal or even better performance [8]. The object of the present study was to provide evidence that prognostic models for overall survival based on clinical variables [4-8] could be improved by information on biological risk factors. By retrospectively analyzing a multicentre CLL population of over 600 untreated patients the most significant and independent biological and clinical prognosticators were integrated in a new clinical-biological prognostic index for group stratification and in a novel nomogram for estimating individual survival.

Methods
Patient population
Between 1996 and 2008 a cohort of 620 CLL patients was collected in the context of a larger multicenter patient dataset (n = 1037), previously utilized to propose a modified prognostic model and nomogram [8], according to the availability of the following biological prognosticators: IGHV mutational status, chromosomal abnormalities, as detected by interphase FISH, and flow cytometric expression of CD38 and ZAP-70. Moreover, since most of the diagnoses of the original patient set were made before the publication of the revised NCI-WG guidelines [1], all cases of previously defined CLL that could be re-classified as monoclonal B cell lymphocytosis (MBL) were removed accordingly. The percentage of recruited cases in the different centers was: 30% at Roma Catholic University, 25% at Novara, 15% at Roma Tor Vergata, 8% at Siena, 6% at Milano, 4% each in the other 4 centers. Cut-points for LNR were as previously reported [3]. Continuous variables age and β2 M levels were categorized using cut-points at 65 years for age and at the upper limit of normal (ULN) for β2 M, as deduced by the analysis of martingale residuals plots [9]; ALC was categorized at the median, since the martingale residual plots did not show any suitable cut-point.

Biological prognosticators
Evaluation of biological prognosticators was centralized in few reference laboratories, utilizing previously validated common procedures; in detail, 5 centers performed IGVH mutational analysis, 6 centers performed cytogenetics and flow cytometry. IGHV mutational status was performed as previously reported [10]. Cytogenetic abnormalities involving chromosomes 11 (del11q22; hereafter del11), 12 (trisomy 12), 13 (13q14.3) and 17 (del17p13; hereafter del17) were investigated by interphase FISH, as reported [11]. Results of FISH analyses were classified as unfavourable when high-risk genomic aberrations (del17p and or del 11q) were present [12-14]. ZAP-70 measurements were determined by flow cytometry, utilizing the 20% of positive CLL cells as cut-off to discriminate between ZAP-70 positive and negative cases [15-18]. CD38 measurements were performed as reported [19], using a threshold at 30% expression to define positive cases. All the variables were measured at or within one year from diagnosis and always before treatment on either fresh or frozen samples. Data were used upon informed consent from patients and approval by Institutional Review Boards (Centro di Riferimento Oncologico, Aviano; Catholic University of the Sacred Heart, Rome), and in accordance with the Declaration of Helsinki.

Statistical methods
All analyses were performed in R, an open source statistical package (http://www.r-project.org/). Median follow-up was computed using the reverse censoring method. The primary end points were overall survival (OS) and time-to-first-treatment (TTT), defined as described [1,20,21]. OS was estimated using Kaplan-Meier plots and compared between groups by log-rank test. Univariate and multivariate Cox models were used to verify independent prognostic power of each parameter. Model minimization was performed by stepwise backward elimination. A p value < 0.05 was considered to be statistically significant. Departure from proportionality in hazard was tested in all Cox models. The predictive accuracy of various Cox models was evaluated by calculating the concordance index.
(c-index), which is a probability of concordance between predicted and observed survival, equal to the area under the receiver operating characteristics curve for censored data [22]. A c-index of 0.5 indicates that outcomes are completely random, whereas a c-index of 1 indicates that the model is a perfect predictor. Prediction error was calculated as 1-c-index. U-statistics was applied to test the significance between different c-index values [22]. Nomo-gram was developed and calibrated following published methods [22]. Final risk group scoring was developed in four step: 1. selection of independent predictive variables; 2. fitting of a Cox model with selected variables; 3. score assignments based on regression coefficients; 4. identification of best cut-point to split the score in 3 risk groups by recursive partitioning [23]. Internal validation for step 1. and 2. was performed with bootstrap .632+ method [24,25] with B = 620 bootstrap samples and (step 2) with cross-validation [26]. Variables selected with a frequency greater than 50% were entered in the final model. Risk score categorical model obtained by recursive partitioning was internally validated by bootstrap methods applied to tree-based analysis [27]. Finally, the whole model building procedure was validated by a comprehensive leave-one-out cross validation (see Additional file 1: supplementary statistical methods). All p values are based on two-tailed tests.

**Results**

**Patients characteristics**

Patients characteristics are reported in Table 1. Treatment was administered according to NCI-WG indications. Deaths occurred mostly in treated patients (83%). Deaths among untreated patients aged beyond 70 years accounted for 11% of all deaths. All patients characteristics were balanced across age groups <55, 55-64, 65-74 and ≥75 (chi-square tests), except for a greater proportion of males in the <55 age group and a greater proportion of high β2 M levels and deaths events in the ≥75 age group. Kaplan-Meyer plots of OS and TTT are shown in Figure 1.

**Univariate and multivariate analysis for OS and TTT**

In univariate analysis for OS all clinical and biological variables were significant, except for del11q (Table 2). The effect of chemoimmunotherapy was small, without statistical significance. The effect of period of diagnosis was significant, with patients diagnosed 2000-2005 and >2005 at increasing risk compared to patients diagnosed before 2001. Based on these results, multivariate analyses were adjusted for the year of diagnosis introduced in the model as a three level stratification factor (≤2000, 2001-2005, >2005). Age dependent variations of variables effects were explored by including an age interaction term either in continuous form or as a four-group (<55, 55-64, 65-74, ≥75) ordinal variable in multivariate models. No significant variations in hazard ratio (HR) values were found (p > 0.05 for all interactions). The selection of the variables entered in final model was internally validated by bootstrap .632+ method [24]. All the variables introduced in the final model were selected in more than 50% of bootstrap samples (Table 3); prediction error in this step of model building was 0.244. The final model fitting was also validated by bootstrap .632+ method, showing at this step a prediction error of 0.247. Leave-one-out cross validation [24,26]. showed that neither β2 M nor gender, the least important variables, could be safely removed from the model (Table 4). Univariate and multivariate analyses of TTT, performed on the subset of Binet A patients below 70 years of age, are shown in Table 5.

| Table 1 Patients characteristics (n = 620) |
|------------------------------------------|
| median age, years (range)               | 65 (21-92) |
| median ALC, x10⁹/L (range)              | 14 (2-460) |
| median β₂M, xULN (range)               | 1.06 (0.13-11.9) |
| LNR ≤3                                  | 25%        |
| Rai stage                               |
| 0                                       | 48%        |
| I-II                                    | 44%        |
| III-IV                                  | 8%         |
| Binet stage                             |
| A                                       | 70%        |
| B                                       | 22%        |
| C                                       | 8%         |
| Male sex                                | 60%        |
| CD38 expression >30%                    | 27%        |
| ZAP-70 expression >20%                  | 41%        |
| Unmutated IgVH                          | 41%        |
| del11q-                                 | 9%         |
| del17p-                                 | 10%        |
| Year of diagnosis                       |
| <=2000                                  | 29%        |
| 2001-2005                               | 49%        |
| >2005                                   | 22%        |
| Treated                                 | 53%        |
| median TTT, years                       | 5.2        |
| Chemotherapy                            | 28%        |
| Chemoimmunotherapy                      | 15%        |
| missing data                            | 10%        |
| Dead                                    | 20%        |
| median OS, years                        | 15         |

ALC, absolute lymphocyte count; LNR, number of lymph node involved regions; ULN, upper limit of normal; β₂ M, beta-2 microglobulin, OS, overall survival; TTT, time to treatment. Complete data (n = 620) available for all variables, except for therapy.
Figure 1 Overall survival (OS) and time to treatment (TTT) in the whole cohort of 620 CLL patients.

Table 2 Univariate and multivariate Cox regression analysis for overall survival

| Variable          | Univariate HR | p       | Initial model HR | p       | Final model HR | p       |
|-------------------|---------------|---------|------------------|---------|----------------|---------|
| Age > 65 years    | 2.99          | <0.0001 | 3.53             | <0.0001 | 3.43           | <0.0001 |
| Male sex          | 1.86          | 0.0018  | 1.84             | 0.0030  | 1.80           | 0.0038  |
| ALC > 14 × 10^9/L | 1.67          | 0.0062  | 1.34             | 0.17    | -              |         |
| b2M > 1 × ULN     | 1.43          | <0.0001 | 1.51             | 0.06    | 1.59           | 0.029   |
| LNR ≥ 3           | 3.06          | <0.0001 | 1.20             | 0.59    | -              |         |
| Binet stage       | <0.0001       |         |                  |         |                |         |
| A                 | ref           |         | ref              |         |                |         |
| B                 | 3.20          |         | 2.19             | 0.0352  | 2.77           | <0.0001 |
| C                 | 4.95          |         | 2.86             | 0.0028  | 3.68           | <0.0001 |
| Rai stage         | <0.0001       |         |                  |         |                |         |
| 0                 | ref           |         | ND               |         |                |         |
| I-II              | 1.66          |         | ND               |         |                |         |
| III-IV            | 5.08          |         | ND               |         |                |         |
| CD38 > 30%        | 1.73          | 0.0038  | 1.03             | 0.88    | -              |         |
| ZAP-70 > 20%      | 1.53          | 0.0204  | 1.04             | 0.83    | -              |         |
| Unmutated IGHV    | 2.46          | <0.0001 | 2.04             | 0.0008  | 2.04           | 0.0003  |
| del17p            | 3.44          | <0.0001 | 2.14             | 0.0015  | 2.06           | 0.0022  |
| del11q            | 1.39          | 0.248   | ND               |         |                |         |
| Year of diagnosis | 0.0130        | (in model as strata)* | (in model as strata)* |         |                |         |
| <2001             | ref           |         |                  |         |                |         |
| 2001-2005         | 1.46          |         |                  |         |                |         |
| >2005             | 2.34          |         |                  |         |                |         |
| Therapy           | 0.106         |         | ND               |         |                |         |
| Chemotherapy      | ref           |         |                  |         |                |         |
| Immunotherapy     | 0.6           |         |                  |         |                |         |

Final model obtained by stepwise backward elimination
HR: hazard ratio; ND: not done

Table 3 Prognostic score for overall survival with clinical and biological risk factors and bootstrap validation

| Variable          | β    | HR    | p     | %    | final score |
|-------------------|------|-------|-------|------|-------------|
| Age > 65 years    | 1.23 | 3.43  | <0.0001 | 100 | 2           |
| Binet B           | 1.02 | 2.77  | <0.0001 | 92  | 2           |
| Binet C           | 1.30 | 3.68  | <0.0001 | 92  | 3           |
| Gender (male)     | 0.59 | 1.80  | 0.0038 | 94  | 1           |
| b2M > 1 × ULN     | 0.46 | 1.59  | 0.0294 | 66  | 1           |
| Del17p            | 0.72 | 2.06  | 0.0022 | 93  | 1           |
| Unmutated IGHV    | 0.71 | 2.04  | 0.0003 | 98  | 1           |
| Calendar year     |      |       |       | 87  |             |

HR: hazard ratio; β: Cox regression coefficient; ULN, upper limit of normal
1 Final model adjusted for year of diagnosis
2 Percentage of selection in 620 leave-one-out bootstrap samples. Percentages for del11, ZAP-70, CD38, LFN, ALC were respectively 28%, 21%, 15%, 24%, 46%
Table 4 Leave-one-out cross validation of the final model

| Step | covariate removed | no. of variables | log-l | AIC | cvlog-l |
|------|------------------|------------------|-------|-----|---------|
| 0    | all (null model) | 0                | -675.7 | -673.7 | -846.8 |
| 1    | none (final model) | 6                | -502.1 | -509.1 | -743.1 |
| 2    | β2M              | 5                | -504.6 | -510.6 | -738.8 |
| 3    | β2M and sex      | 4                | -618.9 | -623.9 | -738.8 |

The final model included the following 6 variables: Binet stage, age > 65 years, unmutated IGHV gene status or 17p deletion (Table 3). The score distribution is reported in Figure 2a. To this end, the validity of the model with 6 variables (according to reference #26)

Clinical-biological prognostic index

The 4-variable clinical model previously proposed by us [8] was refitted in the present CLL cohort (see Additional file 2: Table S1). The 4-variable clinical model had a greater discriminatory power (c-index 0.72) than the 6-variable clinical model by Wierda et al. (c-index 0.62; p = 1.3 × 10⁻⁷). According to the β regression coefficients, a novel clinical-biological prognostic score was developed by assigning 3 points for Binet C stage, 2 points/each for Binet A stage and age > 65 years, 1 point/each for male gender, high β2 M levels, presence of an unmutated IGHV gene status or 17p deletion (Table 3). The score point distribution is reported in Figure 2a. To this end, we applied a recursive partitioning method [23], which yielded three prognostic groups, with score 0-1, 2-5 and 6-9. The Kaplan-Meier plots of the three risk group partitioning of the prognostic score is shown in Figure 2b, for comparison also the risk group partition by Wierda PI [3] is shown in Figure 2c. In particular, 21% of patients (score 0-1) were at low-risk, 63% (score 2-5) were at intermediate risk, and 16% of patients (score 6-9) were at high risk. Projected survival in respectively low, intermediate and high-risk groups was 98%, 90%, 58%, and 98%, 69% 9% at 5-year and 10-year, respectively. Predictive accuracies were significantly greater in the clinical-biological model, compared to the 6-variable clinical model by Wierda et al. (c-index 0.73 vs 0.62, p < 0.0001) [3], or to the 4-variable clinical model (c-index 0.73 vs 0.72, p < 0.0001) [8], or to Binet (c-index 0.73 vs 0.65, p < 0.0001), or Rai (0.73 vs 0.62, p < 0.0001) staging systems.

To show the combination of predictive variables in each patients and in each group we used a heat-map plot (Figure 3). In the low risk group, comprising 133 cases, 52 patients had no adverse predictors (score 0), 50 patients were male, 16 patients had a β2 M > 1 and 15 patients had unmutated IGHV gene mutational status. Of note, low risk patients were never aged >65, nor had a Binet staging B or C, or were affected by a CLL bearing del17p (Figure 4). Conversely, in the high-risk group, only 3 or 4 patients, respectively, had <65 years or a del17p (Figure 4).

Table 5 Univariate and multivariate analysis of TTT in Binet A patients below 70 year of age (n = 291, no missing cases)

|          | univariate |          |          |
|----------|------------|----------|----------|
|          | HR         | p        | HR       | p        | HR       | p        |
| age>65 years | 0.96       | 0.85     | -        |          |          |          |
| male sex | 1.01       | 0.97     | -        |          |          |          |
| ALC>14 × 10⁹/L | 1.35       | 0.0974   | -        |          |          |          |
| β2M>1×ULN   | 2.04       | <0.0001  | 1.53     | 0.0242   | 1.64     | 0.0069   |
| CD38>30%    | 2.46       | <0.0001  | 1.42     | 0.1042   | -        |          |
| ZAP-70>20%  | 2.72       | <0.0001  | 1.39     | 0.1374   | -        |          |
| Unmutated IGHV | 3.60       | <0.0001  | 2.16     | 0.0012   | 3.09     | <0.0001  |
| del17p      | 2.59       | 0.0015   | 1.37     | 0.31     | -        |          |
| del11q      | 3.09       | 0.0005   | 2.21     | 0.02     | 1.97     | 0.0383   |
| Year of diagnosis | 0.85 |          |          |          |          |          |
| <2001      | 0.65       |          |          |          |          |          |
| 2001-2005 | 1.07       |          |          |          |          |          |
| >2005      | 0.89       |          |          |          |          |          |

Final model obtained by stepwise backward elimination

HR, hazard ratio

Nomogram for estimating prognosis in individual patients

Even if individual estimates of survival, as those obtained from nomograms, are more likely affected by inaccuracy than group estimates [28], to allow individual patients survival estimation a nomogram was developed as described previously [8], based on the final model with clinical and biological prognostic factors shown in Table 3, modified using age and β2 M as continuous variables (Figure 5). The clinical-biological nomogram showed a better predictive accuracy than the clinical nomogram proposed by Wierda et al. [3] (c-index respectively 0.79 and 0.76, p = 0.046).

Discussion

Survival time at CLL diagnosis may be simply estimated by means of six variables, four of them clinical-demographic...
(stage, LNR, sex, age) plus two quantitative assays (ALC, β2 M) [3,4,8]. Two independent studies [4,8] failed to confirm the predictive power of ALC. A simplification of the PI from six to four variables was previously proposed by us as capable to stratify patients with equal or better performance [8]. In the present study, the aim was to improve these clinical prognostic models by adding information on biological variables, in particular those identified by the updated NCI-WG guidelines [1] as mandatory at least in the context of clinical trials. We demonstrated that PI for OS prediction based on clinical variables could be improved only by IGHV gene mutational status and del17p, but not CD38, ZAP-70 and del11q. The lack of prognostic power of CD38 and ZAP-70 is not totally unexpected. Similar findings have been found either analyzing OS [13,14,29] or TTT [30,31], although none of these reports included both biological and clinical prognosticators in a comprehensive clinical-biological PI, as proposed here. It has been often emphasized that assays evaluating ZAP-70 and, at least in part, CD38 expression suffer from inherent weakness and lack of proper standardization [13,32-34]. As a consequence, considerable analytic variability still exists on measurement of these parameters [35]. In this regard, such a variability could be more relevant in multi-center series like that investigated in this study. Indeed, at variance with our results, ZAP-70 or CD38 turned out to be among the strongest prognosticators in mono-center studies [36,37], with time-to-first-treatment or time-to-progression as end-points. Lack of reproducibility and standardization of biological markers can affect the results of prognostic tools applied at different institutions. Our model might be less subjected to this bias, since it includes IGHV and del17p, but not the less standardized measurements of CD38 and ZAP-70. Krober et al. [13,14] have previously showed the importance of molecular risk factors in CLL by stratifying patients by IGHV gene mutational status and presence of high-risk genomic aberrations (del17p or del11q), although authors failed to test if their model was independent of clinical and demographic risk factors. Here we had the chance to integrate the data by Krober et al. [13,14] by showing the independent prognostic relevance of UM IGHV gene status and del17p in a model that also included clinical and demographic risk factors. Of note, the effect of these molecular prognosticators was found to be additive and of equal importance. The unexpected limited relevance of molecular risk factors in our model and the lacking predictive power of CD38 and ZAP-70, may be in part justified by a relative small number of deaths and a median follow up of only 5 years, despite the large number of patients collected. Future analyses with longer follow-up data and more events might regain significance to some

Figure 2 Clinical-biological index a) histogram of score points according to clinical-biological prognostic model. Vertical red lines show the positions of cut points splitting sample in 3 risk groups. b) Kaplan-Meyer plot showing prognostic stratification in 3 risk groups according to clinical-biological score. c) prognostic stratification in 3 risk groups according to Wierda et al prognostic score6.
biological variables showing the need to update the score. Compared to our previous clinical model [8], we confirmed the value of $\beta_2$ M, although with the smallest coefficient and the weakest level of significance. We had no data to adjust for renal function impairment, particularly in aged patients, or for other comorbidities. However, $\beta_2$ M was shown to be important in other retrospective and prospective studies [38-40]. The value of prognostic factors in aged CLL patients has been recently criticized by showing that FISH aberrations (del11q or del 17q) and IGVH lost their predictive power for OS in patients aged above 75 years [41]. In our CLL series, we specifically addressed this issue by testing age dependent variations of the predictive power of all the variables included in the final model. No significant interaction effect was found for age. We found a greater proportion of death events in the oldest age group. The risk of death in this group may be influenced by other factors, not related to disease. However, epidemiological data from cancer registry show the frequent occurrence of late deaths attributable to CLL also in aged patients group [42,43]. The effect of chemoimmunotherapy with anti-CD20 was small, with a non significant trend for a longer survival ($p = 0.10$). Results of the present study differed in part from those of a randomized prospective trial [40], where Binet stage and gender, in addition to del11q, CD38 and ZAP-70, all failed to be independent prognostic markers in a multivariate model for OS which also included IGHV gene mutational status,

**Figure 3 Heatmap of individual patient clinical-biological scores** Columns refer to individual patient; rows refer to predictors. In heatmap, each dicotomic predictor is indicated in green or red if present in its favourable or unfavourable configuration, respectively. Binet stages A, B, C are indicated in green, red and black, respectively. Yellow bars show the splits between low, intermediate and high-risk groups. Number of patients in each score class are reported at the bottom of columns.
usage of IGHV3-21 gene, del17p, age and β2 M. Notably, this study, which investigated a population of selected patients in need of treatment (i.e. with active or progressive disease), selected del17p as the strongest risk factor [40]. Conversely, in our retrospective study dealing with untreated patients at diagnosis, the relative weight of del17p appeared equal or lower than that of other variables. Therefore, while the model described in [40] seems to better predict outcome of CLL patients with progressive or active disease, our model appears to be more suited for estimating survival in untreated patients at diagnosis or before clinical progression. The analysis of TTT in Binet A patients below 70 years of age showed that demographic factors (age, gender), important for OS estimation, lost their prognostic power for TTT. Conversely, It might be expected that biological prognosticator, particularly those with limited or even absent significance in the OS analyses, would have gained more importance in the TTT analyses in this subset of patients. However only IGHV and β2 M confirmed their role, with IGHV the most important predictor of TTT. CD38 and ZAP-70 were again not significant, in spite of a good representation of positive cases (respectively 21% and 36%); del17p lost its power whereas del11q gained significance. In this case the low percentage of positive cases may, at least in part, justify the fluctuating results.

Conclusions
In the present study we showed that the survival of untreated CLL patients may be estimated by a limited set of clinical and biological variables, integrated in a prognostic index and in a nomogram, allowing group and individual estimation, respectively. CD38, ZAP-70 and del11q gave redundant prognostic information.
Both the proposed PI and the nomogram were only internally validated. Even in internally validated models, the performance of prognostic tools may be influenced or biased by the composition of the population in which they are developed and lack of standardization of biological variables. Therefore the prognostic tools proposed should be used with caution until externally validated on independent, prospective patient series.

Figure 5 Kaplan-Meyer plots of overall survival (OS) for the 6 variable of the clinical-prognostic index.
Additional material

Additional file 1: Supplementary statistical methods. Details of validation procedures for the whole prognostic model.

Additional file 2: Table S1. Previously proposed prognostic score for overall survival with clinical risk factors.

Abbreviations

ALLC: absolute lymphocyte count; β2M: beta-2-microglobulin; FSH: fluorescence in-situ hybridization; LNR: number of involved lymph node regions; HR: hazard ratio; IGHV: immunoglobulin heavy chain variable gene segments; OS: overall survival; PI: prognostic index; TTT: time to treatment; ULN: upper limit of normal.

Acknowledgements

Authors wish to thank dott. Michela Ternani, Institute of Haematology, Catholic University of the Sacred Heart, Rome, Italy, for clinical data collection. Supported in part by: Ministero della Salute (Ricerca Finalizzata i.R. C.C.S. and “Allaenza contro il Cancro”), Rome; Associazione Italiana contro le Leucemie, Linfomi e mielomi (A.I.L.), Venezia Section, Pramagроме Group; Ricerca Scientifica Applicata, Regione Friuli Venezia Giulia, Trieste (“Linfonet” project); Associazione Italiana per la Ricerca sul Cancro (Investigator Grant IG-8701), Milan, Italy; Helmut Horten Foundation, San Salvatore Foundation; Fondazione per la Ricerca e la Cura sui Linfomi (Lugano, Switzerland); Progetto FIRB-Programma “Futuro in Ricerca” 2008 and PRIN 2008, MIUR, Rome, Italy; AIRC, Special Program Molecular Clinical Oncology, 5 × 1000, No. 10007, Milan, Italy; Progetto Giovani Ricerconato 2008 and Ricerca Sanitaria Finalizzata, Ministero della Salute, Rome, Italy; Ricerca Sanitaria Finalizzata, Regione Piemonte, Torino, Italy. Financial disclosures: none.

Author details

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Dohner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010, 28(29):4473-4479.
2. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, Buhler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Dohner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010, 28(29):4473-4479.
3. Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Döhne K, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognosticnomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007, 109(11):4679-4685.
4. Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hansson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009, 115(2):363-372.
5. Gonzalez Rodriguez AP, Gonzalez Garcia E, Fernandez Alvarez C, Gonzalez Huerta AJ, Gonzalez Rodriguez S. B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA pronostic indexes, Med Clin (Bcn) 2009, 133(3):161-166.
6. Molica S, Di Raimondo F, Cutrona G, Fabris S, Mauro F, Brugiatelli M, Baldini L, Musto P, Sacchi S, Cortelessi A, Foa R, Neri A, Federico M, Ferrari M, Morabito F, Gruppo Italiano Studio Linfomi (GISL). Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. Leuk Res 2010, 34(8):e217-e218.
7. Molica S, Mauro FR, Callea V, Giannarelli D, Laura F, Rotoli B, Cortellezi A, Liso V, Foa R. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica 2010, 95(3):464-469.
8. Bulian P, Tamani M, Rossi D, Forcora F, Del Poeta G, Bertoni F, Zucchi E, Mottillone M, Pozzato G, Deaglio S, D’Arrigo G, Efremov D, Marasca R, Laura F, Gattei V, Gaidano G, Laurenti L. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukemia. Hematol Oncol 2011, 29(2):91-99.
9. Therneau Terry M, Patricia M. Modeling Survival Data: Extending The Cox Model New York Berlin Heidelberg: Springer-Verlag, 2000.
10. Bomber R, Dal Bo M, Capello D, Forcora F, Maffe R, Laurenti L, Rossi D, del Principe M, Zucchetto A, Bertoni F, Rossi FM, Bulian P, Cattarossi I, Iarussi C, Sozzi E, Spina V, Zucchi E, Degan M, Laura F, Del Poeta G, Efremov DG, Marasca R, Gaidano G, Gattei V. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B-cell receptors: results from an Italian multicentre study. Br J Haematol 2009, 144(4):520-526.
11. Dohner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P. Cytogentic and molecular cytotyping analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 1997, 11(Suppl 2):S19-S24.
12. Dohner H, Stilgenbauer S, Benner A, Leupold E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukaemia. N Engl J Med 2000, 343(26):1910-1916.
13. Krober A, Seiler T, Benner A, Bullinger L, Brucke E, Lichter P, Dohner H, Stilgenbauer S. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100(4):1410-1416.
14. Krober A, Bloehdorn J, Hafner S, Krober A, Buhler A, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukaemia. N Engl J Med 2000, 343(26):1910-1916.
15. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Fischke LR, Byrd JC, Kay NE, Greaves M, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351(9):893-901.
16. Crespo M, Bosch F, Villamor N, Bellasio B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348(18):1764-1773.
17. Zucchetto A, Bongomin B, Bo MD, Nanni P, Bulian P, Rossi FM, Del Principe M, Santini S, Del Poeta G, Degan M, Gattei V. ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic)
or internal (T/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom 2006, 70(4):284-292.
18. Rossi FM, Del Principe M, Rossi D, Inno Consalvo M, Luciano F, Zuccetto A, Bulian P, Bomben R, Dai Bo M, Fangazio M, Benedetti D, Degan M, Gandano G, Del Poeta G, Gatti V: Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. J Transl Med 2010, 8:23.
19. Damle RN, Wasli T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Everitt BS, Hothorn T: CD38 gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94(6):1840-1847.
20. Gattei V, Bulian P, Del Principe M, Zuccetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano F, Rossi FM, Degan M, Aramori S, Del Poeta G: Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008, 112(2):865-873.
21. Cheson BD, Pfister J, Juweid ME, Gascoyne RD, Specht L, Hornig SJ, Coiffer B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stoolands S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5):79-86.
22. Harrell FE Jr: Regression Modeling Strategies. New York: Springer; 2001.
23. Everitt BS, Hothorn T: A Handbook of Statistical Analyses Using R. Boca Raton: Chapman & Hall/CRC; 2006.
24. Bradley EL: An introduction to the Bootstrap. Chapman & Hall/CRC; 1993.
25. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15(4):361-387.
26. Verweij P, Van Houwelingen HC: Cross-validation in survival analysis. Stat Med 1993, 12(24):2305-2314.
27. Ishwara H, Kaglaur U, Blackstone E, Lauer M: Random Survival Forests. Ann Appl Stat 2008, 2:2841.
28. Altman DG, Royston P: What do we mean by validating a prognostic model? Stat Med 2000, 19(4):453-473.
29. Oscier DG, Gardiner AC, Mourad A, Morilla A, Gonzalez G, Del Giudice I, Osuji N, Else M, Morilla R, Orlandi EM, Pascutto C, Zibellini S, Pochintesta L, Vanelli L: Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2009, 113(10):4916-4923.
30. Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR: Revised response criteria for malignant lymphoma. Leuk Lymphoma 2004, 49(11):2106-2115.
31. Orlando EM, Pascutto C, Zibellini S, Pochintesta L, Vanelli L: Biological markers and prognostic scoring systems in chronic lymphocytic leukaemia. Br J Haematol 2009, 147(3):402-404.
32. Hamblin TJ: Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007, 20(3):455-468.
33. Ghia P, Guida G, Sciotti C, Geuna M, Caligaris-Cappio F: CD38 modifications in chronic lymphocytic leukemia: are they relevant? Leukemia 2004, 18(10):1733-1735.
34. Marti G, Orfao A, Goolsby C: ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytomtery special issue. Cytometry B Clin Cytom 2006, 70(4):197-200.
35. Van Bockstaele F, Verhasselt B, Philippes J: Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009, 23(1):25-47.
36. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gianni JB, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112(5):1923-1930.
37. Letestu R, Levv Y, Eclave V, Baran-Marzak F, Vaud D, Nague B, Schischmonoff O, Katsahian S, Nguyen-Khac F, Davi F, Merle-Berih H, Troustaud X, Achtenbaum-Cymbalista F: Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood 2010, 116(22):4588-4590.
38. Eichhorst BF, Busch R, Stilgenbauer S, Staub M, Bergmann MA, Ritter M, Kranzhofer N, Robergen S, Ullig G, Westermann A, Goeke V, Schweighofer C, Fischer K, Fink AM, Wendlm CM, Brittinger G, Dohner H, Emmrich B, Hallek M, German CLL Study Group (GCLLSG): First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114(6):3382-3391.
39. Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, De KA, Garcia-Manero G, Czepel J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M: Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009, 27(10):1637-1643.
40. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D, Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute: Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010, 95(10):1705-1712.
41. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalds MS, Schwager SM, Bowen DA, Sleger SL, Hanson CA, Call TG: Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 2010, 116(20):4777-4787.
42. Brenner H, Gondos A, Pulte D: Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1990s to the early 21st century. Blood 2008, 111(10):4916-4923.
43. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Bjorkholm M, Landgren O: Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica 2009, 94(9):1259-1265.